Menu Search
Equities

Cegedim SA

C7E:DUS

Cegedim SA

Actions
  • Price (EUR)14.00
  • Today's Change-0.300 / -2.10%
  • Shares traded45.00
  • 1 Year change-26.55%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cegedim SA is a France-based company that produces and distributes data and services linked to medical information and customer relationship management (CRM) activities for the Sales and Marketing Departments in the Healthcare and Life Sciences sectors. Cegedim is also a manufacturer of medical and para-medical management software, and designs management applications dedicated to the health insurance sector. The Company’s falls into three sectors: Life Sciences which comprises solutions specifically designed for pharmaceutical companies; Healthcare professionals designed for doctors, pharmacists and paramedics, and Healthcare Insurance, which is designed for health insurance providers and for companies of any sectors. The Company operates through Webstar Health and a number of subsidiaries. Cegedim SA is present in approximately 80 countries around the world.

  • Revenue in EUR (TTM)616.00m
  • Net income in EUR-7.41m
  • Incorporated1989
  • Employees6.58k
  • Location
    Cegedim SA137 rue d'AguesseauBOULOGNE-BILLANCOURT 92100FranceFRA
  • Phone+33 149092200
  • Fax+33 146034595
  • Websitehttps://www.cegedim.fr
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		CGM:PAR since
announced		Transaction
value
Groupe Visiodent SASDeal completed15 Feb 202415 Feb 2024Deal completed-15.36%--
Data delayed at least 15 minutes, as of May 17 2024 16:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.